- Author
-
K. Poels
- Title
- Spotlight on immune cell manipulations in atherosclerosis
- Supervisors
-
E. Lutgens
M.P.J. de Winther - Co-supervisors
-
T.T.P. Seijkens
- Award date
- 14 April 2021
- Number of pages
- 201
- ISBN
- 9789464231427
- Document type
- PhD thesis
- Faculty
- Faculty of Medicine (AMC-UvA)
- Abstract
-
Cardiovascular disease (CVD) remains one of the deadliest diseases worldwide. Atherosclerosis, a lipid-driven chronic inflammatory disease, results in plaque formation of the middle and large arteries and consequent rupture can lead to e.g. myocardial infarction. While optimal lipid-lowering strategies have greatly reduced the incidence of atherosclerotic CVD, a residual inflammatory risk remains. Here, we describe several alterations of the immune system and their corresponding results on atherosclerosis.
We identify that Casitas B-cell lymphoma proto-oncogene B (CBL-b), a natural inhibitor of T cell activation, is present in several immune cells in atherosclerotic plaques (e.g. macrophages, T cells) and that its expression is negatively correlated with plaque progression. Furthermore, CBL-b deficiency in Apoe-/- mice exacerbated plaque area, a phenotype which could be rescued with CD8+ T cell depletion, indicating that Cblb-/- CD8+ T cells drove the phenotype.
We then introduce immune checkpoint inhibitors (ICIs), which are antibodies against co-inhibitory molecules that have greatly revised the cancer field, as ICI treatment triggers potent anti-tumor responses. Nevertheless, we hypothesized that this over-activation of T cells could also aggravate atherosclerosis. Indeed, dual antibody-mediated blockade of CTLA4 and PD1 aggravated lesion size in LDLr-/- mice, a find that could have serious ramifications for ICI-treated cancer patients.
Lastly, we examine the effect of PFK158 treatment, which inhibits PFKFB3, the rate-limiting enzyme of glycolysis, the main metabolic driver in pro-inflammatory immune cells. In both murine and human atherosclerotic lesions, PFKFB3 was mainly present in macrophages and endothelial cells and its expression was positively correlated to plaque progression. In LDLr-/- mice, PFK158 treatment reduced plaque progression and stabilized the atherosclerotic lesions. - Persistent Identifier
- https://hdl.handle.net/11245.1/725983ea-8c8c-4597-9734-d1021b92226c
- Downloads
- Supplementary materials
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.